Peritoneal dialysis

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Peritoneal dialysis
Intervention
Peritoneal dialysis.gif
Schematic diagram of peritoneal dialysis
ICD-9-CM 54.98
MeSH D010530

Peritoneal dialysis (PD) is a treatment for patients with severe chronic kidney disease. The process uses the patient's peritoneum in the abdomen as a membrane across which fluids and dissolved substances (electrolytes, urea, glucose, albumin and other small molecules) are exchanged from the blood. Fluid is introduced through a permanent tube in the abdomen and flushed out either every night while the patient sleeps (automatic peritoneal dialysis) or via regular exchanges throughout the day (continuous ambulatory peritoneal dialysis). PD is used as an alternative to hemodialysis though it is far less commonly used in many countries, such as the United States. It has comparable risks but is significantly less costly in most parts of the world, with the primary advantage being the ability to undertake treatment without visiting a medical facility. The primary complication of PD is infection due to the presence of a permanent tube in the abdomen.

Best practices[edit]

Best practices for peritoneal dialysis state that before peritoneal dialysis should be implemented, the patient's understanding of the process and support systems should be assessed, with education on how to care for the catheter and to address any gaps in understanding that may exist. The patient should receive ongoing monitoring to ensure adequate dialysis, and be regularly assessed for complications. Finally, the patient should be educated on the importance of infection control and an appropriate medical regimen established with their cooperation.[1]

Method[edit]

The abdomen is cleaned in preparation for surgery, and a catheter is surgically inserted with one end in the abdomen and the other protruding from the skin.[2] Before each infusion the catheter must be cleaned, and flow into and out of the abdomen tested. A large volume of fluid is introduced to the abdomen over the next ten to fifteen minutes.[3] The total volume is referred to as a dwell[4] while the fluid itself is referred to as dialysate. The dwell can be as much as 2.5 litres, and medication can also be added to the fluid immediately before infusion.[3] The dwell remains in the abdomen and waste products diffuse across the peritoneum from the underlying blood vessels. After a variable period of time depending on the treatment (usually 4–6 hours[3]), the fluid is removed and replaced with fresh fluid. This can occur automatically while the patient is sleeping (automated peritoneal dialysis, APD), or during the day by keeping two litres of fluid in the abdomen at all times, exchanging the fluids four to six times per day (continuous ambulatory peritoneal dialysis, CAPD).[4][5]

The fluid used typically contains sodium, chloride, lactate or bicarbonate and a high percentage of glucose to ensure hyperosmolarity. The amount of dialysis that occurs depends on the volume of the dwell, the regularity of the exchange and the concentration of the fluid. APD cycles between 3 and 10 dwells per night, while CAPD involves four dwells per day of 2-2.5 litres per dwell, with each remaining in the abdomen for 4–8 hours. The viscera accounts for roughly four-fifths of the total surface area of the membrane, but the parietal peritoneum is the more important of the two portions for PD. Two complementary models explain dialysis across the membrane - the three pore model (in which molecules are exchanged across membranes which filter molecules, either proteins, electrolytes or water, based on the size of the pore) and the distributed model (which emphasizes the role of capillaries and the solution's ability to increase the number of active capillaries involved in PD). The high concentration of glucose drives the exchange of fluid from the blood with glucose from the peritoneum. The solute flows from the peritoneal cavity to the organs, and thence into the lymphatic system. Individuals differ in the amount of fluid absorbed through the lymphatic vessels, though it is not understood why. The ability to exchange fluids between the peritoneum and blood supply can be classified as high, low or intermediate. High transporters tend to diffuse substances well (easily exchanging small molecules between blood and the dialysis fluid, with somewhat improved results frequent, short-duration dwells such as with APD) while low transporters filter fluids better (transporting fluids across the membrane into the blood more quickly with somewhat better results with long-term, high-volume dwells such) though in practice either type of transporter can generally be managed through the appropriate use of either APD or CAPD.[6]

Though there are several different shapes and sizes of catheters that can be used, different insertion sites, number of cuffs in the catheter and immobilization, there is no evidence to show any advantages in terms of morbidity, mortality or number of infections, though the quality of information is not yet sufficient to allow for firm conclusions.[7]

Complications[edit]

The volume of dialysate removed as well as patient's weight are monitored. If more than 500ml of fluid are retained or a liter of fluid is lost across three consecutive treatments, the patient's physician is generally notified. Excessive loss of fluid can result in hypovolemic shock or hypotension while excessive fluid retention can result in hypertension and edema. Also monitored is the color of the fluid removed: normally it is pink-tinged for the initial four cycles and clear or pale yellow afterwards. The presence of pink or bloody effluent suggests bleeding inside the abdomen while feces indicates a perforated bowel and cloudy fluid suggests infection. The patient may also experience pain or discomfort if the dialysate is too acidic, too cold or introduced too quickly, while diffuse pain with cloudy discharge may indicate an infection. Severe pain in the rectum or perineum can be the result of an improperly placed catheter. The dwell can also increase pressure on the diaphragm causing impaired breathing, and constipation can interfere with the ability of fluid to flow through the catheter.[3]

A potentially fatal complication estimated to occur in roughly 2.5% of patients is encapsulating peritoneal sclerosis, in which the bowels become obstructed due to the growth of a thick layer of fibrin within the peritoneum.[8]

The fluid used for dialysis uses glucose as a primary osmotic agent, but this may lead to peritonitis, the decline of kidney and peritoneal membrane function and other negative health outcomes. The acidity, high concentration and presence of lactate and products of the degradation of glucose in the solution (particularly the latter) may contribute to these health issues. Solutions that are neutral, use bicarbonate instead of lactate and have few glucose degradation products may offer more health benefits though this has not yet been studied.[9]

Risks and benefits[edit]

PD is less efficient at removing wastes from the body than hemodialysis, and the presence of the tube presents a risk of peritonitis due to the potential to introduce bacteria to the abdomen;[4] peritonitis is best treated through the direct infusion of antibiotics into the peritoneum with no advantage for other frequently used treatments such as routine peritoneal lavage or use of urokinase.[10] The tube site can also become infected; the use of prophylactic nasal mupirocin can reduce the number of tube site infections, but does not help with peritonitis.[11] Infections can be as frequent as once every 15 months (0.8 episodes per patient year). Compared to hemodialysis, PD allows greater patient mobility, produces fewer swings in symptoms due to its continuous nature, and phosphate compounds are better removed, but large amounts of albumin are removed which requires constant monitoring of nutritional status. The costs of PD are generally lower than that of HD in most parts of the world, this cost advantage is most apparent in developed economies. [12] There is insufficient research to adequately compare the risks and benefits between CAPD and APD; a Cochrane Review of three small clinical trials found no difference in clinically important outcomes (i.e. morbidity or mortality) for patients with end stage renal disease, nor was there any advantage in preserving the functionality of the kidneys. The results suggested APD may have psychosocial advantages for younger patients and those who are employed or pursuing an education.[13]

Other complications include hypotension (due to excess fluid exchange and sodium removal), low back pain and hernia or leaking fluid due to high pressure within the abdomen. PD may also be used for patients with cardiac instability as it does not result in rapid and significant alterations to body fluids, and for patients with insulin-dependent diabetes mellitus due to the inability to control blood sugar levels through the catheter. Hypertriglyceridemia and obesity are also concerns due to the large volume of glucose in the fluid, which can add as many as 1200 calories to the diet per day.[14] Of the three types of connection and fluid exchange systems (standard, twin-bag and y-set; the latter two involving two bags and only one connection to the catheter, the y-set uses a single y-shaped connection between the bags involving emptying, flushing out then filling the peritoneum through the same connection) the twin-bag and y-set systems were found superior to conventional systems at preventing peritonitis.[15]

Frequency[edit]

In a 2004 worldwide survey of patients in end stage renal disease, approximately 11% were receiving PD, compared to the much more common hemodialysis. In the United Kingdom, South Korea and Mexico, PD was more common than the world average, with Mexico conducting most of its dialysis (75%) through PD, while Japan and Germany had rates lower than the world average.[16]

Improvised dialysis[edit]

Peritoneal dialysis can be improvised in conditions such as combat surgery or disaster relief using surgical catheters and dialysate made from routinely available medical solutions to provide temporary renal replacement for patients with no other options.[17]

Additional images[edit]

See also[edit]

References[edit]

  1. ^ Wood, M; et al. (2008-08-01). "Nephrology Nursing Standards and Practice Recommendations". Canadian Association of Nephrology Nurses and Technologists. Retrieved 2010-09-08. 
  2. ^ Haralampos V. Harissis et al. A new simplified one port laparoscopic technique of peritoneal dialysis catheter placement with intra-abdominal fixation.The American Journal of Surgery 192 (2006) 125–129 https://www.youtube.com/watch?v=0MuJURb7vpg https://www.researchgate.net/publication/7014798_A_new_simplified_one_port_laparoscopic_technique_of_peritoneal_dialysis_catheter_placement_with_intra-abdominal_fixation?ev=prf_pub
  3. ^ a b c d Best practices: evidence-based nursing procedures. 2007. ISBN 1-58255-532-X. 
  4. ^ a b c Crowley, LV (2009). An Introduction to Human Disease: Pathology and Pathophysiology Correlations. Jones & Bartlett Publishers. pp. 507–509. ISBN 0-7637-6591-0. 
  5. ^ McPhee, SJ; Tierney LM; Papadakis MA (2007). Current medical diagnosis and treatment. McGraw-Hill. pp. 934–935. ISBN 0-07-147247-9. 
  6. ^ Daugirdas, JT; Blake PG; Ing TS (2006). "Physiology of Peritoneal Dialysis". Handbook of dialysis. Lippincott Williams & Wilkins. p. 323. 
  7. ^ Strippoli, GFM; Tong A; Johnson DW; Schena FP; Craig JC (2004). "Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients". In Strippoli, Giovanni FM. Cochrane Database of Systematic Reviews 4 (4): CD004680. doi:10.1002/14651858.CD004680.pub2. PMID 15495125. 
  8. ^ Kawanishi, H.; Moriishi, M. (2007). "Encapsulating peritoneal sclerosis: prevention and treatment". Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 27 Suppl 2: S289–S292. PMID 17556321.  edit
  9. ^ Perl, J.; Nessim, S. J.; Bargman, J. M. (2011). "The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: Benefit at bench, bedside, or both?". Kidney International 79 (8): 814–824. doi:10.1038/ki.2010.515. PMID 21248712.  edit
  10. ^ Wiggins, KJ; Craig JC; Johnson DW; Strippoli GFM; (2008). "Treatment for peritoneal dialysis-associated peritonitis". In Wiggins, Kathryn J. Cochrane Database of Systematic Reviews 1 (1): CD005284. doi:10.1002/14651858.CD005284.pub2. PMID 18254075. 
  11. ^ Strippoli, GFM; Tong A; Johnson DW; Schena FP; Craig JC (2004). "Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients". In Strippoli, Giovanni FM. Cochrane Database of Systematic Reviews 4 (4): CD004679. doi:10.1002/14651858.CD004679.pub2. PMID 15495124. 
  12. ^ Karopadi, AN; Mason G; Rettore E; Ronco C; (2013). "Cost of peritoneal dialysis and haemodialysis across the world". In Zoccali, Carmine. Nephrol Dial Transplant. doi:10.1093/ndt/gft214. PMID 23737482. 
  13. ^ Rabindranath, KS; et al. (2007). "Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease". In Rabindranath, Kannaiyan S. Cochrane Database of Systematic Reviews 2 (2): CD006515. doi:10.1002/14651858.CD006515. PMID 17443624. 
  14. ^ Ehrman, JK; Gordon P; Visich PS; Keteyian SJ (2008). Clinical Exercise Physiology. Human Kinetics. pp. 268–269]. ISBN 0-7360-6565-2. 
  15. ^ Daly, C; et al. (2005). "Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage renal disease". In Daly, Conal. Cochrane Database of Systematic Reviews 1 (2): CD003078. doi:10.1002/14651858.CD003078. PMID 11406068. 
  16. ^ Grassmann, A; Gioberge S; Moeller S; Brown G (2005). "ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends". Nephrology Dialysis Transplantation 20 (12): 2587–2593. doi:10.1093/ndt/gfi159. PMID 16204281. 
  17. ^ Pina, J. S.; Moghadam, S.; Cushner, H. M.; Beilman, G. J.; McAlister, V. C. (2010). "In-Theater Peritoneal Dialysis for Combat-Related Renal Failure". The Journal of Trauma: Injury, Infection, and Critical Care 68 (5): 1253–1256. doi:10.1097/TA.0b013e3181d99089. PMID 20453775.  edit

External links[edit]